Related references
Note: Only part of the references are listed.Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis
Kelvin K. W. Chan et al.
CANCER MEDICINE (2020)
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis
Anouk E. J. Latenstein et al.
ACTA ONCOLOGICA (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Angelique Vienot et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Treatment sequencing in MPC, insights from a 3° care center.
Ivan Barrera et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Jong-Chan Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Sara Pusceddu et al.
CANCERS (2019)
P-335FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group)
F Longo Muñoz et al.
ANNALS OF ONCOLOGY (2019)
P-065A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
J Nakazawa et al.
ANNALS OF ONCOLOGY (2019)
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel A Population-Based Cohort Study
Neha Papneja et al.
PANCREAS (2019)
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
Muhammad Ahsan Javed et al.
PANCREATOLOGY (2019)
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
Ying Wang et al.
JOURNAL OF GASTROINTESTINAL CANCER (2019)
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Nicolas Williet et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
P-161FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study
I Cho et al.
ANNALS OF ONCOLOGY (2018)
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
Junko Tahara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang et al.
INVESTIGATIONAL NEW DRUGS (2018)
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
Hongxuan Tong et al.
SCIENTIFIC REPORTS (2018)
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
Sunnie Kim et al.
ADVANCES IN THERAPY (2018)
Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
Huapyong Kang et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience.
Akihiro Ohba et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis
Takeshi Terashima et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma
Victor Hugo Fonseca de Jesus et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
Kazuo Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
George P. Kim et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
Ali McBride et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
Renata D. Peixoto et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
FOLFIRINOX versus gemcitabine nab-paclitaxel for advanced pancreatic cancer: KU Cancer Center experience.
Anup Kasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Tetsuhito Muranaka et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
Caterina Vivaldi et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Indirect Comparisons and Network Meta-Analyses Estimation of Effects in the Absence of Head-to-Head Trials-Part 22 of a Series on Evaluation of Scientific Publications
Corinna Kiefer et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2015)
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
Ehsan Ghorani et al.
ONCOLOGY (2015)
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
Gillian K. Gresham et al.
BMC CANCER (2014)
Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data
Hansoo Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Graphical Tools for Network Meta-Analysis in STATA
Anna Chaimani et al.
PLOS ONE (2013)
Assessing key assumptions of network meta-analysis: a review of methods
Sarah Donegan et al.
RESEARCH SYNTHESIS METHODS (2013)
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
Georgia Salanti
RESEARCH SYNTHESIS METHODS (2012)
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
Ian R. White et al.
RESEARCH SYNTHESIS METHODS (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multivariate random-effects meta-regression: Updates to mvmeta
Ian R. White
STATA JOURNAL (2011)
Checking consistency in mixed treatment comparison meta-analysis
S. Dias et al.
STATISTICS IN MEDICINE (2010)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer -: A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study
T Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
M Ducreux et al.
ANNALS OF ONCOLOGY (2004)
Share Paper
